<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196179</url>
  </required_header>
  <id_info>
    <org_study_id>ANG-3070-001</org_study_id>
    <nct_id>NCT04196179</nct_id>
  </id_info>
  <brief_title>ANG-3070 in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of ANG-3070 in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angion Biomedica Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angion Biomedica Corp</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study, to assess the safety, tolerability, pharmacokinetics, and food
      effect of single and multiple ascending doses of ANG-3070 in healthy adult participants.

      This study is comprised of 10 cohorts. 6 single ascending dose (SAD) cohorts and 4 multiple
      ascending dose (MAD) cohorts.

      Each cohort will have a total of 8 subjects: SAD and MAD (2 subjects receiving placebo and 6
      subjects receiving active ANG 3070)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study, to assess the safety, tolerability, pharmacokinetics, and food
      effect of single and multiple ascending doses of ANG-3070 in healthy adult participants.

      Each cohort will have a total of 8 subjects: SAD and MAD (2 subjects receiving placebo and 6
      subjects receiving active ANG 3070). The study design employs sentinel dosing with 2 subjects
      (1 placebo, 1 active treatment) at least 24 hours prior to remainder of cohort for dose
      cohort 1.

      SAD cohorts are defined as follows, with the FE crossover occurring for participants in
      cohort A3 on Day 15.

      A1 ANG-3070 50 mg (n=6) / Placebo (n=2)

      A2 ANG-3070 100 mg (n=6) / Placebo (n=2)

      A3 ANG-3070 200 mg (n=6) / Placebo (n=2)

      A3 Day 15** ANG-3070 200mg (n=6) / Placebo (n=2)

      A4 ANG-3070 400 mg (n=6) / Placebo (n=2)

      A5 Day 1 ANG-3070 800 mg (n=6) / Placebo (n=2)

      A6 Day 1 ANG-3070 1200 mg (n=6) / Placebo (n=2)

      MAD cohorts will receive drug or placebo twice daily for 7 consecutive days (Day 1 to Day 7)
      , or once daily for 14 (Day 1 to Day 14) are defined as follows:

      B1 ANG-3070 50 mg (n=6) / Placebo (n=2)

      B2 ANG-3070 100 mg (n=6) / Placebo (n=2)

      B3 ANG-3070 250 mg (n=6) / Placebo (n=2)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Adverse Events</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with adverse events to evaluate safety and tolerability of ANG3070.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Vital Signs</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with abnormal vital signs to evaluate safety and tolerability of ANG3070.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Physical Exam</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with abnormal Physical examination to evaluate safety and tolerability of ANG3070</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Lab Values</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with abnormal lab values to evaluate safety and tolerability of ANG3070.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in ECG QT interval</measure>
    <time_frame>Up to the Follow Up visit 8 days after the last study drug administration</time_frame>
    <description>Difference versus placebo in the number of subjects with abnormal ECG QT interval to evaluate safety and tolerability of ANG3070</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A1 Day 1 ANG-3070 50 mg (n=6) / Placebo (n=2) Oral
A2 Day 1 ANG-3070 100 mg (n=6) / Placebo (n=2) Oral
A3 Day 1 ANG-3070 200 mg (n=6) / Placebo (n=2) Oral
Day 15** ANG-3070 200mg (n=6) / Placebo (n=2) Oral
A4 Day 1 ANG-3070 400 mg (n=6) / Placebo (n=2) Oral
A5 Day 1 ANG-3070 800 mg (n=6) / Placebo (n=2) Oral
A6 Day 1 ANG-3070 1200 mg (n=6) / Placebo (n=2) Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B1 ANG-3070 50 mg (n=6) / Placebo (n=2)
B2 ANG-3070 100 mg (n=6) / Placebo (n=2)
B3 ANG-3070 250 mg (n=6) / Placebo (n=2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG3070</intervention_name>
    <description>ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.</description>
    <arm_group_label>MAD</arm_group_label>
    <arm_group_label>SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>ANG-3070 placebo capsules visually match the drug product.</description>
    <arm_group_label>MAD</arm_group_label>
    <arm_group_label>SAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female volunteers, aged 18 to 65 years (inclusive at the time of
             informed consent);

          2. Participants must be in good general health, with no significant medical history, have
             no clinically significant abnormalities on physical examination at Screening and/or
             before administration of the initial dose of study drug;

          3. Participants must have a minimum body weight of 50 kg and a Body Mass Index (BMI)
             between ≥18.0 and ≤32.0 kg/m2 at Screening;

        Exclusion Criteria:

          1. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at
             any time during the study, including the follow-up period;

          2. Prior or ongoing medical conditions, medical history, physical findings, or laboratory
             abnormality that, in the Investigator's (or delegate's) opinion, could adversely
             affect the safety of the participant;

          3. History of gastrointestinal (GI) disorders such as celiac disease, atrophic gastritis,
             lactose intolerance, and Helicobacter (H.) pylori infection;

          4. Presence of any underlying physical or psychological medical condition that, in the
             opinion of the Investigator, would make it unlikely that the participant will comply
             with the protocol or complete the study per protocol;

          5. Any surgical or medical condition that could interfere with the absorption,
             distribution, metabolism, or excretion of the study drug; 6
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shakil Aslam, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angion Biomedica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shakil Aslam, MD</last_name>
    <phone>857-263-5221</phone>
    <email>saslam@angion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabrielle Pelle</last_name>
    <phone>516-326-1200</phone>
    <email>gpelle@angion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nucleus Network, VIC</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

